CA2717576A1 - Metalloproteinase 9 binding proteins - Google Patents

Metalloproteinase 9 binding proteins Download PDF

Info

Publication number
CA2717576A1
CA2717576A1 CA2717576A CA2717576A CA2717576A1 CA 2717576 A1 CA2717576 A1 CA 2717576A1 CA 2717576 A CA2717576 A CA 2717576A CA 2717576 A CA2717576 A CA 2717576A CA 2717576 A1 CA2717576 A1 CA 2717576A1
Authority
CA
Canada
Prior art keywords
mmp
protein
binding
binding protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2717576A
Other languages
English (en)
French (fr)
Inventor
Laetitia Devy
David Buckler
Edward H. Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA2717576A1 publication Critical patent/CA2717576A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2717576A 2008-03-03 2009-03-03 Metalloproteinase 9 binding proteins Abandoned CA2717576A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3307508P 2008-03-03 2008-03-03
US61/033,075 2008-03-03
US5493808P 2008-05-21 2008-05-21
US61/054,938 2008-05-21
US13829708P 2008-12-17 2008-12-17
US61/138,297 2008-12-17
PCT/US2009/035840 WO2009111450A2 (en) 2008-03-03 2009-03-03 Metalloproteinase 9 binding proteins

Publications (1)

Publication Number Publication Date
CA2717576A1 true CA2717576A1 (en) 2009-09-11

Family

ID=41056597

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717576A Abandoned CA2717576A1 (en) 2008-03-03 2009-03-03 Metalloproteinase 9 binding proteins

Country Status (6)

Country Link
US (2) US8008445B2 (enExample)
EP (1) EP2262529A4 (enExample)
JP (1) JP2011517662A (enExample)
AU (1) AU2009222048A1 (enExample)
CA (1) CA2717576A1 (enExample)
WO (1) WO2009111450A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745587B2 (en) 2005-12-30 2010-06-29 Dyax Corp. Antibodies that bind MMP-14
WO2009079581A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2011028883A2 (en) * 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2011084749A1 (en) * 2009-12-21 2011-07-14 The Research Foundation Of State University Of New York Compositions and methods for inhibiting mmp-9-mediated cell migration
WO2011086548A2 (en) * 2010-01-12 2011-07-21 Ben Gurion University Of The Negev Targeted delivery systems for diagnostic applications
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
JP5877799B2 (ja) * 2010-03-05 2016-03-08 ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリＴｈｅ Ｃｕｒａｔｏｒｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｓｓｏｕｒｉ 変形性関節症のバイオマーカー
WO2011133555A2 (en) 2010-04-20 2011-10-27 The Research Foundation Of State University Of New York Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
WO2012027127A2 (en) * 2010-08-23 2012-03-01 The Ohio State University Research Foundation Elisa for haptoglobin-matrix metalloproteinase 9 complex as a diagnostic test for conditions including acute inflammation
ES2627337T3 (es) 2010-08-26 2017-07-27 F. Hoffmann-La Roche Ag Uso de biomarcadores para controlar una medicación en un sujeto que padece insuficiencia cardíaca
AU2015201367B2 (en) * 2010-08-27 2016-12-15 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9
WO2012027721A2 (en) 2010-08-27 2012-03-01 Gilead Biologics, Inc Antibodies to matrix metalloproteinase 9
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
SG11201405305PA (en) * 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) * 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
KR20150029457A (ko) * 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
FR3015986A1 (fr) * 2013-12-30 2015-07-03 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la proteine mmp-9
CN106062001A (zh) * 2014-02-27 2016-10-26 吉利德科学公司 基质金属蛋白酶9的抗体及其使用方法
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985295A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
PE20181367A1 (es) * 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
JP2016106147A (ja) * 2016-03-14 2016-06-16 ギリアード バイオロジックス， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体
US20200306283A1 (en) 2016-06-22 2020-10-01 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
WO2018129090A1 (en) * 2017-01-03 2018-07-12 Trellis Bioscience, Llc Native human antibodies for immune checkpoint modulation targets tim-3 and b7-h3
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
JP7474736B2 (ja) * 2021-12-27 2024-04-25 花王株式会社 白斑の予防又は改善剤の評価又は選択方法
CN120230208A (zh) * 2024-08-07 2025-07-01 上海交通大学医学院附属第九人民医院 一组sh23同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0736302A3 (en) * 1995-03-23 1997-06-04 Stichting Rega V Z W Protease inhibitors, DNA construction for protease expression and a method for measuring proteases and / or protease inhibitors
GB9809764D0 (en) 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
US7101975B1 (en) * 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
WO2001026671A1 (en) 1999-10-12 2001-04-19 Smithkline Beecham Corporation Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
WO2001090326A2 (en) * 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
AR028606A1 (es) 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
WO2002026829A1 (en) * 2000-09-25 2002-04-04 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
US20070258987A1 (en) * 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AU2002235692A1 (en) * 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
EP1322957B1 (en) * 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
AU2002352089A1 (en) * 2001-11-23 2003-06-10 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
AU2003274059A1 (en) 2002-10-23 2004-05-13 F. Hoffmann-La Roche Ag Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
US7435800B2 (en) * 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
US20050118632A1 (en) * 2003-11-06 2005-06-02 Jian Chen Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b
US20060002969A1 (en) * 2004-01-27 2006-01-05 University Of Washington Methods for reducing the foreign body reaction
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
CN100497324C (zh) 2004-05-27 2009-06-10 武汉科艾硒医药科技发展有限公司 具有抗纤维化及抑制明胶酶活性的化合物及其应用
WO2006036928A2 (en) 2004-09-27 2006-04-06 Wayne State University Inhibitors of matrix metalloproteinases to treat neurological disorders
US20080254490A1 (en) 2005-02-02 2008-10-16 Ramkumar Menon Salivary Protease Assays for Identifying Increased Risk of Preterm Delivery Induced by Premature Rupture of Fetal Membranes
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
US8092819B2 (en) * 2006-01-27 2012-01-10 Cook Medical Technologies LLC. Implantable medical device coated with a bioactive agent
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
BRPI0814479A2 (pt) * 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
KR20090034637A (ko) 2007-10-04 2009-04-08 엘지전자 주식회사 차량용 거치대
WO2009079581A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US8013125B2 (en) * 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
WO2010045388A2 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2011028883A2 (en) 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins

Also Published As

Publication number Publication date
US8008445B2 (en) 2011-08-30
US20090311245A1 (en) 2009-12-17
EP2262529A4 (en) 2013-05-08
WO2009111450A2 (en) 2009-09-11
JP2011517662A (ja) 2011-06-16
US8455205B2 (en) 2013-06-04
EP2262529A2 (en) 2010-12-22
AU2009222048A1 (en) 2009-09-11
WO2009111450A3 (en) 2010-01-07
US20120027774A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
US8013125B2 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8008445B2 (en) Metalloproteinase 9 binding proteins
US8114968B2 (en) Metalloproteinase-12 specific monoclonal antibody
US20110135573A1 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517320A5 (enExample)
JP2011517662A5 (enExample)
US8106168B2 (en) Metalloproteinase binding proteins
WO2010045388A2 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2009097397A2 (en) Metalloproteinase binding proteins
US20100291001A1 (en) Metalloproteinase-binding proteins
US10314909B2 (en) Combination therapy comprising an MMP-14 binding protein
HK1123740B (en) Metalloproteinase binding proteins

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150303